Candela Corporation

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Candela Corporation sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 9 completed later-stage tilt top decile by trial count

Candela Corporation: 12 sponsored US clinical trials, none currently recruiting.

Candela Corporation sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Wrinkle, with 3 trials.

Top-decile sponsor footprint

Candela Corporation ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

12 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

NCT06202274
ACTIVE NOT RECRUITING NA

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071
ACTIVE NOT RECRUITING NA

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

NCT06157567
COMPLETED

A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles

NCT06219278
COMPLETED NA

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

NCT04993066
COMPLETED NA

Functional Usability and Feasibility Testing of the Profound Matrix™ System

NCT06192550
COMPLETED NA

Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions

NCT04202419
COMPLETED NA

Nonablative Fractional Diode Laser for Treatment of Skin Resurfacing and Pigmented Lesions

NCT04203745
COMPLETED Phase 4

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188
COMPLETED NA

PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

NCT03774849
COMPLETED NA

The CO2RE® System for Vulvar Lichen Sclerosus

NCT04148651
COMPLETED

Safety & Efficacy Evaluation of a Radiofrequency & Laser/Light System for Improvement of Skin Texture

NCT01597323

Phase Distribution

PhaseTrial count
Phase 4 1

Therapeutic Areas

Wrinkle 3
Erythematotelangiectatic Rosacea 1
Facial Wrinkles 1
Benign Pigmented Lesions 1
Benign Cutaneous Vascular Lesions 1
Tattoo Removal 1
Hair Reduction 1
Meibomian Gland Dysfunction 1
Skin Conditions 1
Dry Eye Disease 1

How the Candela Corporation archive is shaped

12 indexed studies, none listed as recruiting (0% open); 9 completed (75%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Wrinkle (3 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Candela Corporation: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Candela Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Candela CorporationAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Candela Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Candela Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Candela Corporation page

12 registered trials is a research-attention snapshot, not an endorsement of Candela Corporation or any single study.

  • None of Candela Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Wrinkle is the condition Candela Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Wrinkle trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Candela Corporation pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.